Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 22, 2026

Crypto News: Pepeto Updates Binance Level Exchange And Ethereum Price Prediction Aims $7,500 Despite Crypto Crash

View original at globenewswire.com
Crypto News: Pepeto Updates Binance Level Exchange And Ethereum Price Prediction Aims $7,500 Despite Crypto Crash Dubai, UAE, March 22, 2026 (GLOBE NEWSWIRE) -- The Pepeto team just hit a big milestone on its Binance level exchange, finishing the order book engine and the multi chain liquidity system as the project mov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Multiple research teams predict Ethereum price between $4,500 and $7,500 for end of 2026

    60% confidence

  • Ethereum price at $7,500 gives ETH holders 3.5x returns from current levels

    60% confidence

  • Wider analyst range for Ethereum goes from $4,500 to $10,000 as Glamsterdam upgrade and ETF inflows lift price

    60% confidence

  • Pepeto reaching $100 million market cap from presale pricing gives over 50x returns

    60% confidence

  • Ethereum price will reach $7,500 by end of 2026

    60% confidence

  • The platform runs zero cost swaps on Ethereum, cuts out the gas fees that make small trades pointless on other DeFi platforms, moves coins between Ethereum, BNB Chain, and Solana instantly with no bridging cost, and runs AI checks on every listed token looking for honeypot tricks, hidden mint tools, and rug pull code before it can be traded

    60% confidence

  • Extreme fear lasting 46 straight days has only happened four times since 2018, and every time marked the start of that cycle's biggest recovery

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Crypto News: Pepeto Updates Binance Level Exchange And Ethereum Price Prediction Aims $7,500 Despite Crypto Crash — Source | Via News | ViaNews Market